Response to Hobai - PubMed (original) (raw)

Response to Hobai

Brent Hiramoto et al. Am J Gastroenterol. 2025.

No abstract available

PubMed Disclaimer

Conflict of interest statement

Potential Conflicts of Interest:

Walter Chan served on the advisory board for Phathom Pharmaceuticals, Sanofi Pharmaceuticals, and Regeneron Pharmaceuticals. No other authors have potential conflicts of interest to disclose.

Comment on

• Am J Gastroenterol.
• Gastric Motility Assays May Not Capture the Entire Clinical Picture in Patients Using Glucagon-Like Peptide-1 Receptor Agonists.
  Hobai IA. Hobai IA. Am J Gastroenterol. 2025 Feb 1;120(2):482. doi: 10.14309/ajg.0000000000002949. Epub 2024 Aug 9. Am J Gastroenterol. 2025. PMID: 39120044 No abstract available.

References

1. 1. Hiramoto B, McCarty TR, Lodhia NA, et al. Quantified Metrics of Gastric Emptying Delay by Glucagon-Like Peptide-1 Agonists: A Systematic Review and Meta-Analysis With Insights for Periprocedural Management. Am J Gastroenterol 2024; 119: 1126–40. -PMC -PubMed
2. 1. Hobai IA. Gastric motility assays may not capture the entire clinical picture in patients using GLP-1 receptor agonists. Am J Gastroenterol 2024: This issue. -PubMed
3. 1. Yoshida K, Solomon DH, Kim SC. Active-comparator design and new-user design in observational studies. Nat Rev Rheumatol 2015;11:437–41. -PMC -PubMed
4. 1. Yeo YH, Gaddam S, Ng WH, et al. Increased Risk of Aspiration Pneumonia Associated With Endoscopic Procedures Among Patients With Glucagon-like Peptide 1 Receptor Agonist Use. Gastroenterology 2024. -PubMed
5. 1. Dixit AA, Bateman BT, Hawn MT, et al. Preoperative GLP-1 Receptor Agonist Use and Risk of Postoperative Respiratory Complications. JAMA 2024;331:1672–1673. -PMC -PubMed

LinkOut - more resources

• Full Text Sources

  • Ovid Technologies, Inc.
  • PubMed Central
  • Wolters Kluwer